Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada
Insulin icodec is a cost-effective treatment option for adult patients with T2D versus once daily basal insulin-analogues publicly reimbursed in Canada.
Authors
- David Garcia (ORCID: https://orcid.org/0000-0003-2097-1675)
- Michaela Spence (ORCID: https://orcid.org/0000-0001-9449-2859)
- Morten Sall Jensen (ORCID: https://orcid.org/0000-0001-7157-1220)
- Ronald Goldenberg (ORCID: https://orcid.org/0000-0002-1788-3255)
- G. Mau (ORCID: https://orcid.org/0009-0006-8982-7558)
- Sumeet Singh
Institutions
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (United States) (US)
- LMC Diabetes & Endocrinology (Canada) (CA)
- Novo Nordisk (Italy) (IT)
- EVERSANA (Canada) (CA)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1080/13696998.2025.2551449
- Citations
- 1
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.29